Luveris (Serono)

Luveris (Serono) - General Information

Recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues

Pharmacology of Luveris (Serono)

Used to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. LH also induces the ovulated follicle to become a corpus luteum, which then secretes progesterone.

Additional information about Luveris (Serono)

Luveris (Serono) Indication: For treatment of female infertility
Mechanism Of Action: Binds to the luteinizing hormone receptor which then activates adenylate cylcase through G protein mediation. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Lutropin alfa
Synonyms: LH-B; LSH- beta; LSH-B; Luteinizing hormone beta subunit; Lutropin beta chain precursor
Drug Category: Fertility Agents
Drug Type: Biotech; Approved

Other Brand Names containing Lutropin alfa: Luveris (Serono);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 4.4 hours (mammalian reticulocytes, in vitro)
Dosage Forms of Luveris (Serono): Powder, for solution Subcutaneous
Chemical IUPAC Name: Human luteinizing hormone
Chemical Formula: C1014H1609N287O294S27
Lutropin alfa on Wikipedia: https://en.wikipedia.org/wiki/Lutropin_alfa
Organisms Affected: Humans and other mammals